Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma
Launched by CENTRO ONCOLOGICO DE EXCELENCIA · Jan 26, 2003
Trial Information
Current as of July 30, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES:
* Determine the survival of patients with colon cancer, breast cancer, or melanoma with minimal residual disease after surgical resection treated with maintenance immunotherapy using Corynebacterium granulosum P40.
* Determine leucocyte adherence inhibition, an indication of metastases, over time in patients treated with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified by center and are matched with case-controls by disease type and stage.
Beginning 2 weeks after surgical resection, patients receive Corynebacterium granulosum P40 subcutaneously week...
Gender
ALL
Eligibility criteria
- DISEASE CHARACTERISTICS:
- • Diagnosis of colon cancer, breast cancer, or melanoma with minimal residual disease (at least 90% of tumor mass resected) after surgical resection
- * Hormone receptor status:
- • Not specified
- PATIENT CHARACTERISTICS:
- Age:
- • 20 to 80
- Sex:
- • Not specified
- Menopausal status:
- • Not specified
- Performance status:
- • Not specified
- Life expectancy:
- • Not specified
- Hematopoietic:
- • Not specified
- Hepatic:
- • Not specified
- Renal:
- • Not specified
- PRIOR CONCURRENT THERAPY:
- • Biologic therapy
- • Not specified
- • Chemotherapy
- • Not specified
- • Endocrine therapy
- • Not specified
- • Radiotherapy
- • Not specified
- • Surgery
- • See Disease Characteristics
About Centro Oncologico De Excelencia
Centro Oncológico de Excelencia is a leading clinical trial sponsor dedicated to advancing cancer research and treatment. With a commitment to innovative therapies and patient-centered care, the center collaborates with top-tier medical institutions and researchers to conduct rigorous clinical trials. Its multidisciplinary team of experts focuses on developing cutting-edge oncology solutions, ensuring adherence to the highest ethical and regulatory standards. By fostering collaboration and leveraging the latest scientific advancements, Centro Oncológico de Excelencia aims to improve outcomes for cancer patients and contribute significantly to the global fight against cancer.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gonnet, Buenos Aires, Argentina
Patients applied
Trial Officials
Hugo Omar De Carli, MD
Study Chair
Centro Oncologico de Excelencia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials